Solution-phase synthesis of pyrrole-imidazole polyamides by Chenoweth, David M. et al.
Solution-Phase Synthesis of Pyrrole-Imidazole Polyamides
David M. Chenoweth, Daniel A. Harki, and Peter B. Dervan*
DiVision of Chemistry and Chemical Engineering, California Institute of Technology,
Pasadena, California 91125
Received February 19, 2009; E-mail: dervan@caltech.edu
Abstract: Pyrrole-imidazole polyamides are DNA-binding molecules that are programmable for a large
repertoire of DNA sequences. Typical syntheses of this class of heterocyclic oligomers rely on solid-phase
methods. Solid-phase methodologies offer rapid assembly on a micromole scale sufficient for biophysical
characterizations and cell culture studies. In order to produce gram-scale quantities necessary for efficacy
studies in animals, polyamides must be readily synthesized in solution. An 8-ring hairpin polyamide 1,
which targets the DNA sequence 5′-WGWWCW-3′, was chosen for our synthesis studies as this oligomer
exhibits androgen receptor antagonism in cell culture models of prostate cancer. A convergent solution-
phase synthesis of 1 from a small set of commercially available building blocks is presented which highlights
principles for preparing gram quantities of pyrrole-imidazole oligomers with minimal chromatography.
Introduction
Pyrrole-imidazole polyamides are a class of small molecules
that bind the minor groove of DNA sequence-specifically.1,2
Encoded by side-by-side arrangements of N-methylpyrrole (Py)
and N-methylimidazole (Im) carboxamide monomers, Im/Py
pairs distinguish G ·C from C ·G base pairs, whereas Py/Py pairs
are degenerate for T ·A and A ·T.3 Hairpin Py-Im polyamides
have been shown to bind a broad repertoire of DNA sequences,4
permeate cell membranes and traffic to the nucleus,5 access
chromatin,6 and disrupt protein-DNA interfaces.2 Hairpin
polyamide inhibition of transcription factor-DNA binding of
HIF-1R,7 androgen receptor (AR),8 and AP-19 has been
exploited for controlling expression of medically relevant genes
such as VEGF, PSA, TGF-1, and LOX-1 in cell culture
experiments.
An underpinning to transition polyamide studies from cell
culture to small animal disease models is the ability to synthesize
Py-Im polyamides on gram-scale. Over the years advances in
polyamide solid-phase synthesis have been reported, including
Boc- and Fmoc-based approaches from our laboratories and
others.10 Solid-phase methodologies offer many advantages for
milligram-scale polyamide syntheses, including rapid and reli-
able amino acid couplings and facile purifications owing to
immobilization of the polyamide oligomer on a solid support.
However, these techniques intrinsically limit the scale of
synthesis. Conversely, efficient gram-scale solution-phase meth-
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ods for polyamide synthesis that avoid arduous chromatographic
purifications and employ commercially available Py-Im amino
acid building blocks as reagents are less well developed.
Remarkably, solution-phase synthesis of hairpin polyamides was
the standard in our laboratory prior to the development of solid-
phase methodologies,11a and many variations on this theme have
been published.11 However, laborious chromatographic purifica-
tions and modest reaction yields are commonplace. Therefore,
we sought to develop a general solution-phase polyamide
synthesis method that would allow access to gram quantities of
material in high yield with minimal chromatography.
We report a proof-of-principle study demonstrating that
hairpin Py-Im polyamides can be synthesized in solution from
a small set of building blocks on large scale with minimal use
of chromatography. This method involves Boc-protected dimers,
trimers, and tetramers of heterocycles suitable for convergent
syntheses. By exploiting differences in the physical solubility
properties of starting materials versus products, a solution-phase
synthesis of an 8-ring hairpin Py-Im polyamide 1 (Figure 1)
has been achieved. Notably, our synthesis permits core polya-
mide 2 (Figure 2) to be prepared without a single chromato-
graphic purification, thereby providing large quantities of 2 for
subsequent modification at the C-terminus such as 1. Py-Im
polyamide 1, which targets the DNA sequence 5′-WGWWCW-
3′, was selected for our studies because it antagonizes AR
binding to androgen response elements (ARE) in gene promoters
and regulates a subset of AR-driven genes, such as PSA.5g The
regulation of aberrant AR-activated gene expression in prostate
cancer is a promising strategy for developing novel therapeutics.8
This biological activity, coupled with our desire to conduct small
animal efficacy experiments with 1, renders this polyamide an
ideal candidate for scale-up and optimization studies. In addition,
we discuss unifying principles for planning solution-phase
polyamide syntheses of different Py-Im arrangements.
Results and Discussion
Our retrosynthetic approach for the preparation of an 8-ring
hairpin polyamide, ImPyPyPy-(R)-H2Nγ-ImPyPyPy-(+)-IPA (1),
is shown in Figure 2. Sequential couplings of ImPyPyPy
tetramer 3 to turn moiety 5, followed by ester saponification
and coupling to PyPyPy trimer 4, afford polyamide 2 in a
convergent manner. Advanced intermediates 3-5 were prepared
from building blocks 6-10,12 which have been previously
synthesized by our laboratory and others.10a,c,13 The cornerstone
of our synthesis strategy capitalizes on the disparate physical
properties of starting materials versus products, which permit
purification of each intermediate to be achieved by combinations
of precipitation, trituration, and crystallization. Such details are
described below.
The synthesis of pyrrole trimer 4 begins with pyrrole amine
salt 10 (Scheme 1). Amide coupling of 10 with activated pyrrole
monomer 7 affords dimer 11 in 93% yield. The utilization of a
small excess of 10 relative to 7 drives the reaction to completion,
and residual 10 is readily separated from 11 following precipita-
tion in water and aqueous washing of the residual solid 11.
Reaction of dimer 11 with anhydrous HCl in diethyl ether
removes the carbamate protecting group and facilitates precipi-
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Figure 1. Structure of Py-Im hairpin polyamide 1 targeting the DNA
sequence 5′-WGWWCW-3′ and its ball-and-stick representation.
Figure 2. Retrosynthetic strategy for the convergent solution-phase
synthesis of polyamide 1. 7-10 are commercially available building blocks.
Boc ) tert-butyl carbamate, Bt ) benzotriazole, Cbz ) benzyl carbamate.
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tation of 12 as the HCl salt during the course of the reaction.
Isolation of solid 12 by filtration, followed by washing of the
residual solid with excess Et2O, provides the amine HCl salt in
99% yield. By exploiting the aqueous solubility of 10 versus
insolubility of 11, PyPy dimer 11 is easily purified from a small
excess of 10 by precipitation, whereas deprotected 12 is
separable from Boc-protected 11 by virtue of the Et2O solubility
of 11 versus insolubility of 12. This reaction sequence highlights
our synthesis strategy: exploiting the different solubility profiles
of reactants versus products for chromatography-free purifica-
tions. Accordingly, pyrrole trimer 4 was obtained from dimer
12 by coupling with 7, followed by acidic deprotection to yield
4 in 95% yield (two steps) from dimer 12. The ImPyPyPy
tetramer 3 was synthesized in two steps from trimer 4. 1-Methyl-
2-trichloroacetylimidazole (6), prepared in one step from
N-methylimidazole,10c,13 was allowed to react with a small
excess of 4 to deliver tetramer 14 in 83% yield following
precipitation in H2O, trituration with Et2O, and drying in Vacuo.
Saponification of 14 with aqueous NaOH in 1,4-dioxane,
followed by neutralization with aqueous HCl, precipitation, and
Et2O trituration, afforded tetramer 3 in 77% overall yield from
trimer 4.
The Im-turn fragment 5 was synthesized in two steps from
the Im ·HCl salt monomer10a 9 by coupling to PyBOP-activated
(R)-3,4-Cbz-Dbu(Boc)-OH (8), yielding protected dimer 15 in
95% yield (Scheme 2). The utilization of a small excess of 9
drives the coupling reaction to completion and is easily separated
in the aqueous wash step. Removal of the carbamate protecting
group with anhydrous HCl in 1,4-dioxane yielded the final
synthon for our studies, imidazole-turn dimer 5, in quantitative
yield following filtration and washing of the residual salt. With
compound 5 in hand, the assembly of core polyamide 2 was
initiated. PyBOP-mediated coupling of tetramer 3 to a small
excess of water-soluble Im-turn dimer 5 yielded the advanced
intermediate 16 in 97% yield. Saponification of 16 to acid 17,
followed by amide coupling with an excess of water-soluble
trimer 4, delivered core Py-Im hairpin polyamide 2 in 88% yield
for the two steps. Consistent with the previously discussed
strategy for synthesizing intermediates 3-5, the differences in
solubility of reactants versus products were exploited to isolate
pure material by precipitation, washing, and trituration. In most
cases a low-boiling-point solvent was employed in the final
trituration step to facilitate efficient solvent removal in Vacuo.
Core polyamide 2 was synthesized without a single chromato-
graphic purification in high overall purity, as depicted by the
analytical HPLC analysis of 2 shown in Figure 3. Multigram
quantities of 2 have been readily synthesized by this method,
providing a stockpile of material for elaboration at the C-
terminus into discrete polyamide conjugates, such as 1.
Py-Im polyamide 1 was synthesized in solution from ad-
vanced core 2 by coupling the preassembled C-terminal tail
moiety 21 with saponified core 22. This convergent approach
Scheme 1. Preparation of 3 and 4a
a Reagents and conditions: (i) DMF, DIEA, 7, 23 °C, 8 h, 93%; (ii) 2.0
M HCl in Et2O, 23 °C, 18 h, 99%; (iii) DMF, DIEA, 7, 23 °C, 8 h, 96%;
(iv) 4.0 M HCl in 1,4-dioxane, 23 °C, 18 h, 99%; (v) DMF, DIEA, 6, 23
°C, 2 h, 83%; (vi) NaOH(aq), 1,4-dioxane, 42 °C, 2 h, 93%.
Scheme 2. Preparation of 5 and Assembly of Core Polyamide 2a
a Reagents and conditions: (i) DMF, DIEA, PyBOP, (R)-3,4-Cbz-
Dbu(Boc)-OH (8), 23 °C, 8 h, 95%; (ii) HCl in 1,4-dioxane, 23 °C, 16 h,
99%; (iii) DMF, DIEA, PyBOP, 3, 23 °C, 2 h, 97%; (iv) KOH(aq), MeOH,
1,4-dioxane, 42 °C, 2 h, 92%; (i) DMF, DIEA, PyBOP, 4, 23 °C, 10 h,
96%.
Figure 3. Analysis of polyamide 2 purity by analytical HPLC. Wavelength
shown is 310 nm.
J. AM. CHEM. SOC. 9 VOL. 131, NO. 20, 2009 7177
Solution-Phase Synthesis of Py-Im Polyamides A R T I C L E S
begins by preparing Boc-protected C-terminus moiety 20
(Scheme 3). PyBOP-mediated coupling of mono-Boc-protected
triamine linker 1814 with monobenzyl-protected isophthalic acid
1915 afforded Boc-protected 20 in 98% yield. Deprotection of
20 with anhydrous CF3CO2H in dichloromethane (1:1) yielded
amine 21, which was used immediately following concentration
under high vacuum. Saponification of core polyamide 2 with
aqueous NaOH in 1,4-dioxane at 23 °C yielded 8-ring acid 22
in 89% yield (Scheme 4). The transformation of 2 to 22 proved
somewhat difficult in early studies due to formation of an
unidentified side product. Avoiding reaction temperatures above
23 °C suppresses most of the byproduct formation, whereas a
screen of aqueous bases commonly used for ester saponification
(KOH and LiOH) failed to identify a better reagent. Coupling
of residual acid 22 with freshly prepared 21 delivered the
penultimate oligomer 23 in 87% yield. Unfortunately, crude
oligomer 23 could not be satisfactorily purified by our standard
method and required chromatography on silica gel to achieve
pure material. Hundreds of milligrams of 23 have been prepared
by this method in a single reaction sequence. Global deprotection
of 23 by hydrogenation (Pd/C, ∼1 atm H2) at 23 °C for 48 h
yields Py-Im polyamide 1 in 81% yield. Final product 1 can be
separated from residual catalyst by solid-phase extraction and
then purified by preparative reverse-phase HPLC.
With multi-milligram quantities of 1 on hand, we investigated
in detail the UV properties of Py-Im polyamide 1 in a variety
of laboratory and biologically relevant solvents. As shown in
Figure 4, a strong solvent influence on the molar extinction
coefficient of 1 is observed as the amount of organic cosolvent
is increased. For example, an extinction coefficient (ε, M-1
cm-1) of 26 500 was measured for 1 in distilled and deionized
H2O, whereas this value doubled to 54 800 in 50% acetonitrile
in aqueous CF3CO2H (0.1% v/v CF3CO2H), a widely utilized
laboratory solvent for purifying and quantifying peptides. A
stock solution frequently encountered for preparing biological
samples, 10% DMSO in DEPC-treated H2O yielded an inter-
mediary value of 40 900 M-1cm-1. Hence, care must be taken
to consider the solvent system utilized when performing UV
spectroscopy to determine polyamide concentrations.
Conclusion
A solution-phase synthesis of Py-Im hairpin polyamide 1 is
presented, highlighting unifying principles for the preparation
of related polyamides. A convergent synthesis was developed,
requiring no chromatographic purifications to arrive at core
8-ring polyamide 2 on multigram scale. Final elaboration of
the C-terminus affords AR polyamide antagonist 1 in high yield.
The synthetic methodology permits gram-scale synthesis of Py-
Im polyamides, a minimum next step as we transition these small
molecules to animal models for biological efficacy.
Experimental Section
General. Chemicals were purchased from Sigma-Aldrich and
were used without further purification. (R)-3,4-Cbz-Dbu(Boc)-OH
was purchased from Senn Chemicals AG (code number 44159).
Bulk grade solvents were from Fisher Scientific. Centrifugation was
performed in a Beckman Coulter benchtop centrifuge (Allegra 21R)
equipped with a Beckman swing-out rotor (model S4180). Analyti-
cal HPLC analysis was conducted on a Beckman Gold instrument
equipped with a Phenomenex Gemini analytical column (250 ×
4.6 mm, 5 µm) and a diode array detector, and the mobile phase
consisted of a gradient of acetonitrile (MeCN) in 0.1% (v/v) aqueous
CF3CO2H. Preparative HPLC was performed on an Agilent 1200
system equipped with a solvent degasser, a diode array detector,
and a Phenomenex Gemini column (250 × 21.2 mm, 5 µm). A
gradient of MeCN in 0.1% (v/v) aqueous CF3CO2H was utilized
as the mobile phase. UV-vis measurements were made on a
Hewlett-Packard diode array spectrophotometer (model 8452 A).
NMR spectroscopy was performed on a Varian instrument operating
at 499.8 MHz (for 1H) or 125.7 MHz (for 13C) at ambient
temperature. All NMR analyses were performed in DMSO-d6, and
chemical shifts are reported in parts per million relative to the
internal solvent peak referenced to 2.49 (for 1H) or 39.5 (for 13C).
High-resolution mass spectrometry (HRMS) was recorded in
positive-ion mode by fast-atom bombardment (FAB+) on a JEOL
JMS-600H instrument or by electrospray ionization (ESI+) on a
Waters Acquity UPLC-LCT Premiere XE TOF-MS system.
HCl ·H2N-Py-CO2Me (10). Prepared as previously described.10a
1H NMR: δ 10.09 (br s, 3H), 7.25 (d, J ) 2.0 Hz, 1H), 6.80 (d, J
) 2.2 Hz, 1H), 3.85 (s, 3H), 3.74 (s, 3H). 13C NMR: δ 160.2, 123.7,
120.8, 113.9, 111.4, 51.3, 36.6. HRMS (FAB+): calcd for
C7H11N2O2 [M + H]+, 155.0821; found, 155.0847.
BocHN-PyPy-CO2Me (11). A solution of BocHN-Py-OBt 7
(6.16 g, 17.2 mmol) and HCl ·H2N-Py-CO2Me 10 (3.61 g, 19.0
mmol) in DMF (39 mL) and DIEA (6 mL, 34.4 mmol) was stirred
at 23 °C for 8 h. The solution was then added to distilled H2O
(14) Dervan, P. B.; Sluka, J. P. Design of sequence-specific DNA binding
molecules: bis(distamycin)phenoxazone. In New Synthetic Meth-
odology and Functionally Interesting Compounds; Yoshida, Z., Ed.;
Studies in Organic Chemistry 25; Elsevier: Amsterdam, 1986; pp 307-
322.
(15) Adlington, R. M.; Baldwin, J. E.; Becker, G. W.; Chen, B.; Cheng,
L.; Cooper, S. L.; Hermann, R. B.; Howe, T. J.; McCoull, W.;
McNulty, A. M.; Neubauer, B. L.; Pritchard, G. J. J. Med. Chem.
2001, 44, 1491–1508.
Scheme 3. Preparation of 21a
a Reagents and conditions: (i) DMF, DIEA, PyBOP, 23 °C, 3 h, 98%;
(ii) CF3CO2H, CH2Cl2, 23 °C, 20 min, concentration in Vacuo and used
crude.
Scheme 4. Final Steps for the Synthesis of Py-Im Polyamide 1a
a Reagents and conditions: (i) NaOH(aq), 1,4-dioxane, 23 °C, 11 h, 89%;
(ii) DIEA, DMF, PyBOP, 21, 23 °C, 12 h, 87%; (iii) DMF, Pd/C, H2 (1
atm), 23 °C, 48 h, 81%.
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(500 mL) preacidified with aqueous HCl (1 N, 300 mL, 300 mmol),
yielding a precipitate that was isolated by centrifugation (∼4500
rpm). The residual solid was again suspended in distilled H2O (80
mL) and collected by centrifugation (repeated 2×). The resultant
solid, which contained a small amount of residual H2O, was frozen
and lyophilized to dryness. Drying of the light-brown solid in Vacuo
yielded dimer 11 (6.03 g, 93%). 1H NMR: δ 9.84 (s, 1H), 9.10 (s,
1H), 7.44 (d, J ) 1.7 Hz, 1H), 6.88 (m, 2H), 6.82 (s, 1H), 3.82 (s,
3H), 3.79 (s, 3H), 3.72 (s, 3H), 1.44 (s, 9H). 13C NMR: δ 160.8,
158.4, 152.8, 123.0, 122.6, 122.4, 120.7, 118.4, 117.1, 108.3, 103.8,
78.3, 50.9, 36.1, 36.0, 28.2. HRMS (FAB+): calcd for C18H25N4O5
[M + H]+, 377.1825; found, 377.1835.
HCl ·H2N-PyPy-CO2Me (12). Dimer 11 (4.0 g, 10.6 mmol) in
a solution of anhydrous HCl in Et2O (2.0 M, 400 mL) was stirred
at 23 °C for 18 h. The mixture was then diluted with 400 mL of
anhydrous Et2O and filtered over a sintered glass funnel. The
resultant solid was washed with copious amounts of anhydrous Et2O
and dried in Vacuo to yield dimer 12 as a tan solid (3.3 g, 99%).
1H NMR: δ 10.12 (s, 1H), 10.07 (br s, 3H), 7.46 (d, J ) 2.0 Hz,
1H), 7.10 (d, J ) 2.0 Hz, 1H), 7.00 (d, J ) 2.0 Hz, 1H), 6.91 (d,
J ) 2.0 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.72 (s, 3H). 13C NMR:
δ 160.8, 157.7, 124.6, 122.6, 121.7, 120.8, 118.6, 113.1, 108.4,
107.2, 51.0, 36.6, 36.2. HRMS (FAB+): calcd for C13H17N4O3
[M + H]+, 277.1301; found, 277.1292.
BocHN-PyPyPy-CO2Me (13). A solution of BocHN-Py-OBt 7
(3.1 g, 8.7 mmol) and dimer 12 (3.0 g, 9.59 mmol) in DMF (20
mL) and DIEA (3 mL, 17.4 mmol) was stirred at 23 °C for 8 h.
The solution was then added to distilled H2O (250 mL) preacidified
with aqueous HCl (1 N, 150 mL, 150 mmol), yielding a precipitate
that was isolated by centrifugation (∼4500 rpm). The residual solid
was again suspended in distilled H2O (40 mL) and collected by
centrifugation (repeated 2×). The resultant solid, which contained
a small amount of residual H2O, was frozen and lyophilized to
dryness. Drying of the light-brown solid in Vacuo yielded trimer
13 (4.17 g, 96%). 1H NMR: δ 9.91 (s, 1H), 9.86 (s, 1H), 9.09 (s,
1H), 7.46 (d, J ) 2.0 Hz, 1H), 7.21 (d, J ) 1.7 Hz, 1H), 7.05 (d,
J ) 1.5 Hz, 1H), 6.89 (m, 2H), 6.83 (s, 1H), 3.83 (s, 6H), 3.80 (s,
3H), 3.73 (s, 3H), 1.45 (s, 9H). 13C NMR: δ 160.8, 158.5, 158.4,
152.8, 123.0, 122.8, 122.4, 122.30, 122.29, 120.7, 118.48, 118.47,
117.0, 108.3, 104.8, 103.8, 78.3, 50.9, 36.2, 36.05, 36.04, 28.2.
HRMS (FAB+): calcd for C24H30N6O6 [M•]+, 498.2227; found,
498.2233.
HCl ·H2N-PyPyPy-CO2Me (4). Dimer 13 (4.0 g, 8.02 mmol)
in a solution of anhydrous HCl in 1,4-dioxane (4.0 M, 300 mL)
was stirred at 23 °C for 18 h. The mixture was then diluted with
600 mL of anhydrous Et2O and filtered over a sintered glass funnel.
The resultant solid was washed with copious amounts of anhydrous
Et2O and dried in Vacuo to yield trimer 4 as a brown-orange solid
(3.45 g, 99%). 1H NMR: δ 10.16 (s, 3H), 10.13 (s, 1H), 9.97 (s,
1H), 7.46 (d, J ) 2.0 Hz, 1H), 7.25 (d, J ) 1.7 Hz, 1H), 7.11 (d,
J ) 2.0 Hz, 1H), 7.08 (d, J ) 2.0 Hz, 1H), 7.02 (d, J ) 2.0 Hz,
1H), 6.91 (d, J ) 2.0 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.82 (s,
3H), 3.72 (s, 3H). 13C NMR: δ 160.8, 158.4, 157.7, 124.8, 123.0,
122.6, 121.9, 121.6, 120.8, 118.7, 118.5, 113.0, 108.4, 107.2, 104.8,
51.0, 36.6, 36.2, 36.1. HRMS (FAB+): calcd for C19H22N6O4 [M•]+,
398.1702; found, 398.1685.
ImPyPyPy-CO2Me (14). A solution of trimer 4 (1.019 g, 2.34
mmol) and 1-methyl-2-trichloroacetylimidazole (6)10c,13 (478 mg,
2.10 mmol) in DMF (4.5 mL) and DIEA (910 µL, 5.22 mmol)
was stirred at 23 °C for 2 h. The solution was then added to distilled
H2O (40 mL) preacidified with aqueous HCl (1N, 910 µL, 0.91
mmol), yielding a precipitate that was isolated by centrifugation
(∼4500 rpm). The residual solid was again suspended in distilled
H2O (40 mL) and collected by centrifugation (repeated 1×). The
resultant solid, which contained a small amount of residual H2O,
was frozen and lyophilized to dryness. The solid was triturated with
anhydrous Et2O and filtered over a sintered glass funnel. The
resultant solid was washed with copious amounts of anhydrous Et2O
and dried in Vacuo to yield tetramer 14 as a light brown solid (886
mg, 83%). 1H NMR: δ 10.68 (s, 1H), 10.00 (s, 1H), 9.94 (s, 1H),
7.48 (s, 1H), 7.47 (d, J ) 2.0 Hz, 1H), 7.31 (d, J ) 1.7 Hz, 1H),
7.24 (d, J ) 1.7 Hz, 1H), 7.18 (s, 1H), 7.17 (d, J ) 2.0 Hz, 1H),
7.08 (d, J ) 2.0 Hz, 1H), 6.91 (d, J ) 1.7 Hz, 1H), 4.01 (s, 3H),
3.86 (s, 3H), 3.84 (s, 3H), 3.83 (s, 3H), 3.73 (s, 3H). 13C NMR: δ
160.8, 158.5, 158.4, 155.0, 138.2, 126.4, 125.6, 123.1, 123.0, 122.5,
122.2, 121.2, 120.7, 118.8, 118.6, 118.5, 108.3, 104.9, 104.8, 50.9,
36.18, 36.17, 36.1, 35.4. HRMS (FAB+): calcd for C24H27N8O5
[M + H]+, 507.2104; found, 507.2116.
ImPyPyPy-CO2H (3). A solution of tetramer 14 (804 mg, 1.59
mmol) in 1,4-dioxane (8 mL) and aqueous NaOH (1 N, 8.0 mL,
8.00 mmol) was stirred at 42 °C for 2 h. The solution was then
added to distilled H2O (40 mL) preacidified with aqueous HCl (1
N, 8 mL, 8.00 mmol), yielding a precipitate that was isolated by
centrifugation (∼4500 rpm). The residual solid was again suspended
in distilled H2O (40 mL) and collected by centrifugation (repeated
1×). The resultant solid, which contained a small amount of residual
H2O, was frozen and lyophilized to dryness. The solid was triturated
with anhydrous Et2O and filtered over a sintered glass funnel. The
resultant solid was washed with copious amounts of anhydrous Et2O
and dried in Vacuo to yield tetramer 3 as a brown solid (728 mg,
93%). 1H NMR: δ 10.45 (s, 1H), 9.97 (s, 1H), 9.91 (s, 1H), 7.43
(s, 1H), 7.38 (s, 1H), 7.29 (s, 1H), 7.24 (s, 1H), 7.17 (s, 1H), 7.07
(s, 1H), 7.03 (s, 1H), 6.85 (s, 1H), 3.99 (s, 3H), 3.85 (s, 3H), 3.84
(s, 3H), 3.82 (s, 3H). 13C NMR: δ 162.0, 158.48, 158.46, 156.1,
138.8, 127.0, 126.4, 123.0, 122.7, 122.6, 122.2, 121.5, 120.3, 119.5,
Figure 4. UV properties of polyamide 1 in solvent systems I-VIII. (A) UV traces of I-VIII from 250-600 nm and (B) tabular form of data. Molar
extinction coefficients were calculated from the λmax for each individual system, which ranged from 313 to 317 nm. DEPC ) diethylpyrocarbonate-treated
H2O.
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118.7, 118.5, 108.4, 105.0, 104.8, 36.14, 36.07, 35.1. HRMS
(FAB+): calcd for C23H25N8O5 [M + H]+, 493.1948; found,
493.1952.
BocHN-(R)-CbzHNγ-Im-CO2Et (15). A solution of (R)-3,4-Cbz-
Dbu(Boc)-OH 8 (1.03 g, 2.93 mmol) and PyBOP (1.83 g, 3.51
mmol) in DMF (12 mL) and DIEA (1.5 mL, 8.8 mmol) was stirred
at 23 °C for 22 min. The solution was then added to solid
(powdered) HCl ·H2N-Im-CO2Et 9 (850 mg, 3.15 mmol) and stirred
at 23 °C for 8 h. This solution was then added to distilled H2O (30
mL) preacidified with aqueous HCl (1 N, 9 mL, 9 mmol), yielding
a precipitate that was isolated by centrifugation (∼ 4500 rpm). The
residual solid was again suspended in distilled H2O (40 mL) and
collected by centrifugation (repeated 2×). The resultant solid, which
contained a small amount of residual H2O, was frozen and
lyophilized to dryness. Drying of the brown solid in Vacuo yielded
dimer 15 (1.4 g, 95%). 1H NMR: δ 10.57 (s, 1H), 7.51 (s, 1H),
7.31-7.27 (m, 5H), 7.02 (d, J ) 8.5 Hz, 1H), 6.79 (m, 1H), 4.97
(s, 2H), 4.25 (q, J ) 7.2 Hz, 2H), 3.93 (m, 1H), 3.89 (s, 3H), 3.01
(m, 2H), 2.44-2.35 (m, 2H), 1.35 (s, 9H), 1.27 (t, J ) 7.2 Hz,
3H). 13C NMR: δ 167.6, 158.4, 155.8, 155.4, 137.4, 137.1, 130.7,
128.2, 127.6, 127.5, 114.8, 77.7, 65.1, 60.5, 48.6, 43.5, 38.1, 35.4,
28.2, 14.0. HRMS (FAB+): calcd for C24H34N5O7 [M + H]+,
504.2458; found, 504.2462.
HCl ·H2N-(R)-CbzHNγ-Im-CO2Et (5). Dimer 15 (500 mg, 0.993
mmol) in a solution of anhydrous HCl in 1,4-dioxane (4.0 M, 10
mL) and anhydrous Et2O (4 mL) was stirred at 23 °C for 16 h.
The mixture was then diluted with 20 mL of anhydrous Et2O and
filtered over a sintered glass funnel. The resultant solid was washed
with copious amounts of anhydrous Et2O and dried in Vacuo to
yield dimer 5 as a white solid (432 mg, 99%). 1H NMR: δ 10.75
(s, 1H), 8.05 (m, 3H), 7.52 (s, 1H), 7.38 (d, J ) 8.5 Hz, 1H),
7.34-7.28 (m, 5H), 5.01 (m, 2H), 4.25 (q, J ) 7.1 Hz, 2H), 4.13
(m, 1H), 3.90 (s, 3H), 2.96-2.84 (m, 2H), 2.60-2.51 (m, 2H),
1.27 (t, J ) 7.1 Hz, 3H). 13C NMR: δ 166.8, 158.4, 155.7, 137.2,
136.8, 130.9, 128.3, 127.8, 127.7, 114.9, 65.5, 60.6, 46.6, 42.1,
38.2, 35.4, 14.0. HRMS (FAB+): calcd for C19H26N5O5 [M + H]+,
404.1934; found, 404.1928.
ImPyPyPy-(R)-CbzHNγ-Im-CO2Et (16). A solution of tetramer
3 (1.28 g, 2.59 mmol) and PyBOP (1.49 g, 2.86 mmol) in DMF (8
mL) and DIEA (1.8 mL, 10.4 mmol) was stirred at 23 °C for 20
min. The solution was then treated with solid (powdered) HCl ·H2N-
(R)-CbzHNγ-Im-CO2Et 5 (1.2 g, 2.73 mmol) and stirred at 23 °C
for 2 h. This solution was then added to distilled H2O (30 mL)
preacidified with aqueous HCl (1 N, 20 mL, 20 mmol), yielding a
precipitate that was isolated by centrifugation (∼4500 rpm). The
residual solid was again suspended in distilled H2O (40 mL) and
collected by centrifugation (repeated 2×). The resultant solid, which
contained a small amount of residual H2O, was frozen and
lyophilized to dryness. The solid was triturated with anhydrous Et2O
and filtered over a sintered glass funnel. The resultant solid was
washed with copious amounts of anhydrous Et2O and dried in Vacuo
to yield ImPyPyPy-(R)-CbzHNγ-Im-CO2Et 16 as a tan solid (2.2 g,
97%). 1H NMR: δ 10.60 (s, 1H), 10.46 (s, 1H), 9.96 (s, 1H), 9.91
(s, 1H), 7.97 (t, J ) 5.6 Hz, 1H), 7.52 (s, 1H), 7.39 (s, 1H),
7.29-7.26 (m, 6H), 7.24 (m, 1H), 7.18-7.14 (m, 3H), 7.04 (m,
2H), 6.90 (m, 1H), 4.98 (m, 2H), 4.24 (q, J ) 7.1 Hz, 2H), 4.10
(m, 1H), 3.99 (s, 3H), 3.89 (s, 3H), 3.845 (s, 3H), 3.839 (s, 3H),
3.77 (s, 3H), 3.29 (m, 2H), 2.49 (m, 2H, obstructed by NMR
solvent), 1.27 (t, J ) 7.2 Hz, 3H). 13C NMR: δ 167.7, 161.5, 158.49,
158.48, 158.45, 156.0, 155.6, 138.7, 137.4, 137.1, 130.8, 128.2,
127.7, 127.6, 126.8, 126.4, 123.0, 122.8, 122.7, 122.24, 122.17,
121.4, 118.7, 118.5, 118.0, 114.9, 105.0, 104.7, 104.4, 65.2, 60.5,
48.6, 42.1, 38.2, 36.13, 36.11, 36.0, 35.4, 35.2, 14.0. HRMS
(FAB+): calcd for C42H48N13O9 [M + H]+, 878.3698; found,
878.3668.
ImPyPyPy-(R)-CbzHNγ-Im-CO2H (17). A solution of ImPy-
PyPy-(R)-CbzHNγ-Im-CO2Et 16 (2.0 g, 2.28 mmol) dissolved in 1,4-
dioxane (2 mL), MeOH (6 mL), and aqueous KOH (1N, 9.1 mL,
9.1 mmol) was stirred at 42 °C for 2 h. The solution was then
acidified with aqueous HCl (1 N, ∼9.1 mL, ∼9.1 mmol) to a pH
) 4.5, yielding a precipitate that was isolated by centrifugation
(∼4500 rpm). The residual solid was again suspended in distilled
H2O (10 mL) and collected by centrifugation (repeated 1×). The
resultant solid, which contained a small amount of residual H2O,
was frozen and lyophilized to dryness. The solid was triturated with
anhydrous Et2O and filtered over a sintered glass funnel. The
resultant solid was washed with copious amounts of anhydrous Et2O
and dried in Vacuo to yield ImPyPyPy-(R)-CbzHNγ-Im-CO2H 17 as
a tan solid (1.78 g, 92%). 1H NMR: δ 10.50 (s, 1H), 10.47 (s, 1H),
9.96 (s, 1H), 9.92 (s, 1H), 7.98 (m, 1H), 7.48 (s, 1H), 7.40 (s, 1H),
7.30-7.27 (m, 6H), 7.24 (m, 1H), 7.19-7.14 (m, 3H), 7.05 (m,
2H), 6.90 (m, 1H), 4.99 (m, 2H), 4.10 (m, 1H), 3.99 (s, 3H), 3.88
(s, 3H), 3.845 (s, 3H), 3.838 (s, 3H), 3.77 (s, 3H), 3.30 (m, 2H),
2.49 (m, 2H, obstructed by NMR solvent). 13C NMR: δ 167.7,
161.5, 160.0, 158.5, 155.8, 155.6, 138.6, 137.1, 131.6, 128.3, 127.7,
127.6, 126.7, 126.4, 123.0, 122.8, 122.7, 122.23, 122.16, 121.4,
118.7, 118.5, 118.0, 114.6, 105.0, 104.7, 104.4, 65.2, 48.6, 42.2,
38.2, 36.13, 36.10, 36.0, 35.4, 35.2. HRMS (FAB+): calcd for
C40H44N13O9 [M + H]+, 850.3385; found, 850.3383.
ImPyPyPy-(R)-CbzHNγ-ImPyPyPy-CO2Me (2). A solution of
ImPyPyPy-(R)-CbzHNγ-Im-CO2H 17 (1.5 g, 1.77 mmol) and PyBOP
(546 mg, 1.85 mmol) in DMF (8.8 mL) and DIEA (922 µL, 5.3
mmol) was stirred at 23 °C for 10 min. The solution was then treated
with solid (powdered) HCl ·H2N-PyPyPy-CO2Me 4 (806 mg, 1.85
mmol) and stirred at 23 °C for 10 h. This solution was then added
to distilled H2O (35 mL) preacidified with aqueous HCl (1 N, 5
mL, 5 mmol), yielding a precipitate that was isolated by centrifuga-
tion (∼4500 rpm). The residual solid was again suspended in
distilled H2O (40 mL) and collected by centrifugation (repeated
3×). The resultant solid, which contained a small amount of residual
H2O, was frozen and lyophilized to dryness. The solid was triturated
with anhydrous Et2O and filtered over a sintered glass funnel. The
resultant solid was washed with copious amounts of anhydrous Et2O
and dried in Vacuo to yield ImPyPyPy-(R)-CbzHNγ-ImPyPyPy-
CO2Me 2 as a tan solid (2.09 g, 96%). 1H NMR: δ 10.66 (s, 1H),
10.21 (s, 1H), 10.00 (s, 1H), 9.98 (s, 1H), 9.96 (s, 1H), 9.93 (s,
1H), 9.92 (s, 1H), 8.00 (m, 1H), 7.48 (s, 1H), 7.46 (d, J ) 2.0 Hz,
1H), 7.45 (s, 1H), 7.31-7.27 (m, 7H), 7.23 (m, 2H), 7.20-7.14
(m, 5H), 7.06 (m, 2H), 6.92 (m, 1H), 6.90 (d, J ) 2.0 Hz, 1H),
5.00 (m, 2H), 4.11 (m, 1H), 4.00 (s, 3H), 3.95 (s, 3H), 3.854 (s,
3H), 3.850 (s, 3H), 3.842 (s, 3H), 3.837 (s, 3H), 3.828 (s, 3H),
3.78 (s, 3H), 3.73 (s, 3H), 3.32 (m, 2H), 2.53 (m, 2H). 13C NMR:
δ 167.9, 161.6, 160.8, 158.5, 158.42, 158.38, 155.8, 155.6, 137.6,
137.1, 136.0, 134.0, 128.3, 127.7, 127.6, 126.4, 123.3, 123.1, 123.0,
122.80, 122.77, 122.5, 122.26, 122.24, 122.1, 121.2, 120.9, 120.8,
118.9, 118.70, 118.64, 118.5, 118.0, 114.1, 108.4, 104.9, 104.79,
104.76, 104.5, 65.2, 51.0, 48.8, 42.2, 38.4, 36.25, 36.21, 36.19,
36.13, 36.10, 36.0, 35.8, 35.0. HRMS (FAB+): calcd for
C59H64N19O12 [M + H]+, 1230.498; found, 1230.504.
ImPyPyPy-(R)-CbzHNγ-ImPyPyPy-CO2H (22). A solution of
polyamide 2 (500 mg, 0.406 mmol) dissolved in 1,4-dioxane (8
mL) and aqueous NaOH (1 N, 8.0 mL, 8.0 mmol) was stirred at
23 °C for 11 h. The solution was then cooled to 0 °C in an ice bath
and the pH adjusted to pH ) 4.0 with aqueous HCl (1 N, ∼8 mL,
8 mmol), yielding a precipitate that was isolated by centrifugation
(∼4500 rpm). The residual solid was again suspended in distilled
H2O (40 mL) and collected by centrifugation (repeated 2×). The
resultant solid, which contained a small amount of residual H2O,
was frozen and lyophilized to dryness. The solid was triturated with
anhydrous Et2O and filtered over a sintered glass funnel. The
resultant solid was washed with copious amounts of anhydrous Et2O
and dried in Vacuo to yield ImPyPyPy-(R)-CbzHNγ-ImPyPyPy-CO2H
22 as a tan solid (442 mg, 89%). 1H NMR: δ 10.52 (s, 1H), 10.22
(s, 1H), 10.00 (s, 1H), 9.97 (s, 1H), 9.95 (s, 1H), 9.93 (s, 1H), 9.90
(s, 1H), 8.00 (m, 1H), 7.45 (s, 1H), 7.42 (m, 2H), 7.30-7.27 (m,
7H), 7.24 (m, 2H), 7.19-7.14 (m, 4H), 7.09 (s, 1H), 7.06 (m, 2H),
6.92 (m, 1H), 6.84 (d, J ) 2.0 Hz, 1H), 5.01 (m, 2H), 4.11 (m,
1H), 3.99 (s, 3H), 3.95 (s, 3H), 3.851 (s, 3H), 3.848 (s, 3H), 3.843
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(s, 3H), 3.838 (s, 3H), 3.81 (s, 3H), 3.79 (s, 3H), 3.32 (m, 2H),
2.53 (m, 2H). 13C NMR: δ 167.9, 162.0, 161.6, 158.48, 158.47,
158.44, 158.40, 155.8, 155.6, 138.6, 137.1, 136.0, 134.0, 128.3,
127.7, 127.6, 126.4, 123.06, 123.05, 122.8, 122.74, 122.70, 122.6,
122.24, 122.19, 122.15, 121.4, 121.2, 120.3, 119.5, 118.7, 118.55,
118.47, 118.0, 114.1, 108.4, 104.9, 104.86, 104.80, 104.75, 104.5,
65.2, 48.7, 42.2, 38.3, 36.2, 36.13, 36.10, 36.07, 35.97, 35.2, 34.9.
HRMS (FAB+): calcd for C58H62N19O12 [M+H]+, 1216.483; found,
1216.487.
BocHN-(+)-BnOIPA (20). A solution of acid 1915 (211 mg, 0.824
mmol) and PyBOP (624 mg, 1.2 mmol) in DMF (3 mL) and DIEA
(211 µL, 1.2 mmol) was stirred at 23 °C for 10 min. Protected
triamine 1814 (373 mg, 1.52 mmol) was then added to the solution,
and stirring was continued at 23 °C for 3 h. The solution was then
added to distilled H2O (15 mL), and a viscous oil was isolated
following centrifugation (∼4500 rpm) and decanting of the aqueous
layer. The residual oil was again washed with distilled H2O (10
mL) and collected by centrifugation (repeated 3×). Drying of the
residual oil in Vacuo yielded BocHN-(+)-BnOIPA 20 as a viscous
amber oil (391 mg, 98%). 1H NMR: δ 8.77 (t, J ) 5.5 Hz, 1H),
8.43 (app t, J ) 1.5 Hz, 1H), 8.14-8.09 (m, 2H), 7.63 (app t, J )
7.8 Hz, 1H), 7.48-7.34 (m, 5H), 6.85 (t, J ) 4.9 Hz, 1H), 5.38 (s,
2H), 3.30 (m, 2H), 3.00 (m, 1H), 2.94 (m, 2H), 2.72-2.51 (m,
4H), 2.38 (br s, 3H), 1.75 (m, 2H), 1.59 (m, 2H), 1.34 (s, 9H). 13C
NMR: δ 165.3, 165.2, 155.6, 136.0, 135.0, 131.9, 131.7, 129.8,
129.0, 128.6, 128.2, 128.1, 127.9, 77.5, 66.4, 54.3, 54.0, 40.6, 37.7,
37.3, 28.2, 25.9, 25.5. HRMS (FAB+): calcd for C27H38N3O5
[M+H]+, 484.2811; found, 484.2793.
ImPyPyPy-(R)-CbzHNγ-ImPyPyPy-(+)-BnOIPA (23). A solution
of ImPyPyPy-(R)-CbzHNγ-ImPyPyPy-CO2H 22 (192 mg, 0.158
mmol) and PyBOP (99 mg, 0.189 mmol) in DMF (2 mL) and DIEA
(220 µL, 1.3 mmol) was stirred at 23 °C for 30 min. In a separate
vial, BocHN-(+)-BnOIPA 20 (122 mg, 0.252 mmol) was deprotected
by treating with a solution of CH2Cl2:CF3CO2H (1:1, 2 mL) for 20
min at 23 °C, followed by concentration to dryness in Vacuo. This
residual material was then treated with the preactivated solution of
ImPyPyPy-(R)-CbzHNγ-ImPyPyPy-CO2H 22 and allowed to stir at
23 °C for 12 h. The solution was then added to distilled H2O (30
mL) preacidified with aqueous HCl (1 N, 2 mL, 2 mmol), yielding
a precipitate that was isolated by centrifugation (∼4500 rpm). The
residual solid was again suspended in distilled H2O (40 mL) and
collected by centrifugation (repeated 3×). The resultant solid, which
contained a small amount of residual H2O, was frozen and
lyophilized to dryness. The residual brown solid was purified by
SiO2 chromatography with the mobile phase consisting of a step
gradient of 49:1 CH2Cl2:MeOH to 44:5:1 CH2Cl2:MeOH:NH3 to
provide ImPyPyPy-(R)-CbzHNγ-ImPyPyPy-(+)-BnOIPA 23 as a tan
solid (217 mg, 87%) after drying under high vacuum. 1H NMR: δ
10.43 (s, 1H), 10.20 (s, 1H), 9.98 (s, 1H), 9.95 (s, 1H), 9.93 (s,
1H), 9.92 (s, 1H), 9.87 (s, 1H), 8.73 (t, J ) 5.5 Hz, 1H), 8.41 (app
t, J ) 1.6 Hz, 1H), 8.11-8.07 (m, 2H), 8.03-7.98 (m, 2H), 7.60
(app t, J ) 7.7 Hz, 1H), 7.48-7.32 (m, 7H), 7.30-7.23 (m, 9H),
7.19-7.14 (m, 5H), 7.06 (d, J ) 1.7 Hz, 1H), 7.05 (d, J ) 1.7 Hz,
1H), 7.03 (d, J ) 1.0 Hz, 1H), 6.92 (d, J ) 1.2 Hz, 1H), 6.84 (d,
J ) 1.7 Hz, 1H), 5.37 (s, 2H), 5.00 (m, 2H), 4.11 (m, 1H), 3.99 (s,
3H), 3.95 (s, 3H), 3.85 (s, 3H), 3.84 (m, 6H), 3.83 (s, 3H), 3.79 (s,
3H), 3.77 (s, 3H), 3.30 (m, 4H), 3.18 (m, 2H), 2.53 (m, 2H), 2.35
(m, 4H), 2.16 (br s, 3H), 1.71-1.60 (m, 4H). 13C NMR: δ 167.9,
165.20, 165.16, 161.6, 161.2, 158.50, 158.46, 158.42, 156.1, 155.8,
155.6, 138.8, 137.1, 136.0, 135.2, 134.0, 131.9, 131.6, 129.7, 129.0,
128.5, 128.3, 128.2, 128.1, 128.0, 127.8, 127.7, 127.6, 127.00,
126.99, 126.3, 123.1, 123.0, 122.80, 122.77, 122.75, 122.26, 122.18,
122.14, 122.11, 121.4, 121.2, 118.7, 118.5, 118.0, 117.7, 114.1,
105.0, 104.9, 104.8, 104.5, 104.1, 66.4, 65.2, 55.1, 55.0, 48.8, 42.2,
41.6, 38.3, 37.9, 37.0, 36.2, 36.10, 36.09, 36.07, 35.96, 35.89, 35.1,
34.9, 26.9, 26.6. HRMS (ESI+): calcd for C80H89N22O14 [M + H]+,
1581.6929; found, 1581.6992.
ImPyPyPy-(R)-H2Nγ-ImPyPyPy-(+)-IPA (1). A solution of
ImPyPyPy-(R)-CbzHNγ-ImPyPyPy-(+)-BnOIPA 23 (25 mg, 0.016
mmol) and Pd/C (10 wt % dry, 10 mg) in DMF (2 mL) was stirred
at 23 °C for 48 h under H2 (∼1 atm, balloon). [Note: The protecting
groups are cleaved at different rates, and early reaction aliquots
will reveal a monoprotected compound.] The reaction was then
filtered through a Sep-Pak cartridge (5 g of C-18 sorbent), and the
Sep-Pak was washed with DMF (4 mL), aqueous MeCN (50%, 20
mL), MeCN (250 mL), and MeOH (250 mL). The filtrate was then
concentrated in Vacuo, purified by reverse-phase HPLC, and
lyophilized to dryness. The solid was triturated with anhydrous Et2O
and filtered over a sintered glass funnel. The resultant solid was
washed with copious amounts of anhydrous Et2O and dried in Vacuo
to yield ImPyPyPy-(R)-H2Nγ-ImPyPyPy-(+)-IPA 1 as a light tan
solid (18.9 mg, 81%). 1H NMR: δ 10.61 (s, 1H), 10.46 (s, 1H),
9.95 (s, 2H), 9.94 (s, 1H), 9.92 (s, 1H), 9.89 (s, 1H), 9.46 (br s,
1H), 8.82 (t, J ) 5.8 Hz, 1H), 8.42 (app t, J ) 1.4 Hz, 1H), 8.20
(m, 1H), 8.15 (m, 1H), 8.08 (d, J ) 1.7 Hz, 1H), 8.07 (d, J ) 1.7
Hz, 1H), 7.97 (m, 3H), 7.60 (app t, J ) 7.6 Hz, 1H), 7.45 (s, 1H),
7.40 (d, J ) 0.7 Hz, 1H), 7.28 (d, J ) 2.0 Hz, 1H), 7.26 (d, J )
1.7 Hz, 1H), 7.22 (d, J ) 2.0 Hz, 1H), 7.21 (d, J ) 1.7 Hz, 1H),
7.18 (d, J ) 1.7 Hz, 1H), 7.16 (m, 2H), 7.15 (d, J ) 1.7 Hz, 1H),
7.08 (m, 2H), 7.05 (d, J ) 1.0 Hz, 1H), 7.03 (d, J ) 1.7 Hz, 1H),
6.94 (d, J ) 1.8 Hz, 1H), 3.99 (s, 3H), 3.96 (s, 3H), 3.85 (s, 3H),
3.844 (s, 3H), 3.842 (s, 3H), 3.83 (s, 3H), 3.82 (s, 3H), 3.79 (s,
3H), 3.69 (m, 1H), 3.44 (m, 2H), 3.35 (m, 2H), 3.24 (m, 2H),
3.18-3.12 (m, 2H), 3.11-3.04 (m, 2H), 2.76 (m, 3H), 2.50 (m,
2H, obstructed by NMR solvent), 1.95-1.91 (m, 2H), 1.90-1.83
(m, 2H). 13C NMR: δ 166.84, 166.82, 165.7, 162.1, 161.6, 158.52,
158.49, 158.40, 158.1, 157.8, 156.0, 155.7, 138.7, 135.6, 134.6,
134.2, 131.9, 131.5, 131.0, 128.7, 128.0, 126.9, 126.3, 123.1, 123.0,
122.8, 122.7, 122.5, 122.4, 122.24, 122.16, 122.10, 121.4, 121.1,
118.7, 118.5, 118.3, 118.0, 115.7, 105.0, 104.9, 104.8, 104.54,
104.52, 59.2, 53.3, 48.2, 36.5, 36.2, 36.08, 36.07, 35.99, 35.6, 35.38,
35.35, 35.1, 35.0, 24.3, 24.0. HRMS (ESI+): calcd for C65H77N22O12
[M + H]+, 1357.6086; found, 1357.6091.
Calculation of Molar Extinction Coefficients. Solid 1 (0.51
mg, 0.35 µmol) was weighed into a tared vial on a microbalance
(Sartorius Micro M4). A molecular weight of 1471.46 was utilized
for 1, which assumes 1 exists as the CF3CO2H salt. The material
was dissolved in distilled and deionized H2O (1000 µL), yielding
a 0.35 µM stock solution. Fifty-fold dilutions of this stock solution
were made into the appropriate solvent systems (Figure 4). Data
were collected at 23 °C in a 1 cm quartz cuvette, and molar
extinction coefficients are based on the λmax for each solvent system
(range: 313-317 nm). The instrument was blanked on each discrete
solvent system prior to data collection. Duplicate analysis of each
sample yielded similar results (data not shown). A second polyamide
stock solution was generated by dissolving solid 1 in 50% MeCN
in aqueous CF3CO2H (0.1% v/v), followed by 50-fold dilution into
the individual solvent systems, and data collection yielded results
similar to those shown in Figure 4 (data not shown). DEPC-treated
H2O (RNase- and DNase-free) was purchased from USB Corp.
EtOH was absolute grade from Pharmaco-AAPER, and DMSO was
molecular biology grade from Sigma-Aldrich. DMF was anhydrous
synthesis grade from Sigma-Aldrich, and acetonitrile was HPLC
grade from Fisher.
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